Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care

Background Irritable bowel syndrome (IBS) is a common functional bowel disorder that has a considerable impact on patient quality of life and substantial societal and health care resource costs. Current treatments are often ineffective. Tricyclic antidepressants have shown promise in secondary care...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current controlled trials in cardiovascular medicine Jg. 23; H. 1; S. 552 - 12
Hauptverfasser:	Alderson, Sarah L., Wright-Hughes, Alexandra, Ford, Alexander C., Farrin, Amanda, Hartley, Suzanne, Fernandez, Catherine, Taylor, Christopher, Ow, Pei Loo, Teasdale, Emma, Howdon, Daniel, Guthrie, Elspeth, Foy, Robbie, Ridd, Matthew J., Bishop, Felicity L., Muir, Delia, Chaddock, Matthew, Herbert, Amy, Cooper, Deborah, Gibbins, Ruth, Newman, Sonia, Cook, Heather, Longo, Roberta, Everitt, Hazel
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 08.07.2022 BioMed Central Ltd Springer Nature B.V BMC
Schlagworte:	Amitriptyline Biomedicine Care and treatment Celiac disease Cost analysis Dosage and administration Double-blind Double-blind studies Health Sciences Irritable bowel syndrome Laxatives Medicine Medicine & Public Health Objectives Patients Placebo Primary care Qualitative research Quality of life Questionnaires Randomised controlled trial Self report Statistics for Life Sciences Study Protocol Testing United Kingdom Amitriptyline Double-blind Primary care Irritable bowel syndrome Placebo Randomised controlled trial
ISSN:	1745-6215, 1745-6215
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!